Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of March PADAC Meeting

Related THRX
Glaxosmithkline, Theravance Intend to File Relvar Ellipta for COPD in Japan
Theravance Just Lost Its Catalyst

Stifel Nicolaus maintained Theravance (NASDAQ: THRX) with a Buy rating and lowered the price target from $40.00 to $37.00.

Stifel Nicolaus commented, "We expect the release of BREO briefing docs (likely March 4th/5th) and subsequent PADAC meeting to likely generate a meaningful amount of volatility in the stock. However, we continue to like the risk/reward at current levels and remain Buy-rated with $37 target price."

Theravance closed at $21.60 on Tuesday.

Latest Ratings for THRX

May 2015Cowen & CompanyDowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings


Related Articles (THRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters